RCUS

Arcus Biosciences Inc

17.43

Nov 13 • 3:59 PM ET -0.34 (-1.91%)

17.43

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NYSE

Peers: EXEL XNCR IDYA SMMT MRK CBIO RVMD IOVA AGEN GILD

| Held by: IJR VTI IWM XBI VXF VB SPSM XSMO VBK VTWO

Scroll to Statements

Index	RUT
Market Cap	2.51B
Enterprise Value	2.00B
Income	-453.00M
Sales	100.00M
Book/sh	2.81
Cash/sh	4.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	601
IPO	Mar 15, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	25.10
P/B	6.21
P/C	3.98
P/FCF	-
EV/EBITDA	-
EV/Sales	19.96
Quick Ratio	3.34
Current Ratio	3.34
Debt/Eq	0.32
LT Debt/Eq	0.28
Option/Short	Yes / Yes

EPS (ttm)	-3.64
EPS next Y	-3.26
EPS next Q	-0.86
EPS this Y	-9.95%
EPS next Y	9.79%
EPS next 5Y	1.31%
EPS past 3/5Y	3.94% -7.95%
Sales past 3/5Y	30.16% 26.08%
EPS Y/Y TTM	-6.14%
Sales Y/Y TTM	-58.33%
EPS Q/Q	20.74%
Sales Q/Q	-65.38%
Earnings	Nov 04 AMC
EPS/Sales Surpr.	-12.26% 18.72%

Insider Own	32.85%
Insider Trans	-0.22%
Inst Own	62.84%
Inst Trans	0.29%
ROA	-50.56%
ROE	-114.11%
ROIC	-98.48%
Gross Margin	91.00%
Oper. Margin	-475.00%
Profit Margin	-453.00%
SMA20	-7.69%
SMA50	-22.94%
SMA200	-28.77%
Trades

Shs Outstand	127.60M
Shs Float	96.69M
Short Float	13.63%
Short Ratio	7.19
Short Interest	13.18M
52W High	31.74 -45.08%
52W Low	17.43 0.00%
Volatility	4.69% 7.51%
ATR (14)	1.21
RSI (14)	35.06
Beta	1.09
Rel Volume	0.62
Avg Volume	1.83M
Volume	1,138,781

Perf Week	-4.65%
Perf Month	-23.62%
Perf Quarter	-41.04%
Perf Half Y	-26.70%
Perf YTD	-26.86%
Perf Year	-11.93%
Perf 3Y	29.78%
Perf 5Y	-54.23%
Perf 10Y	-
Recom	1.27
Target Price	41.00
Prev Close	17.77
Price	17.43
Change %	-1.91%

Consensus

Strong Buy

Avg. Price Target

$41.00

Implied Upside

+135.2%

Analysts17incl. previous ratings

Rating Distribution14 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 16, 2026	Initiated	WWilliam Blair	Outperform
Oct 14, 2026	Initiated	JJP Morgan	Overweight	$41	+135.2%
Sep 16, 2026	Initiated	TTD Cowen	Buy
May 18, 2026	Resumed	TTruist	Buy	$35	+100.8%
Feb 12, 2026	Downgrade	WWells Fargo	Overweight → Equal Weight	$23	+32.0%
Jan 13, 2026	Upgrade	GGoldman	Neutral → Buy	$28	+60.6%
Jan 08, 2026	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$20	+14.7%
Feb 26, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$18 → $24	+37.7%
Oct 21, 2024	Initiated	HH.C. Wainwright	Neutral	$20	+14.7%
Oct 08, 2024	Initiated	WWells Fargo	Overweight	$29	+66.4%
Nov 18, 2022	Initiated	BBofA Securities	Neutral	$33	+89.3%
Oct 11, 2022	Initiated	MMorgan Stanley	Overweight	$40	+129.5%
Oct 15, 2021	Resumed	BBTIG Research	Buy	$57	+227.0%
Nov 24, 2020	Initiated	BBerenberg	Buy	$50	+186.9%
Nov 23, 2020	Initiated	EEvercore ISI	Outperform
Apr 03, 2020	Initiated	CCantor Fitzgerald	Overweight	$21	+20.5%
Mar 04, 2020	Initiated	BBarclays	Overweight	$24	+37.7%
Nov 12, 2019	Initiated	SSunTrust	Buy	$20	+14.7%
Sep 27, 2019	Initiated	MMizuho	Buy	$22	+26.2%
May 24, 2019	Resumed	CCitigroup	Buy	$25	+43.4%

Nov-06-26 09:13AM	Wedbush Revises Best Ideas List After October Underperformance (Investing.com)
Nov-04-26 04:05PM	Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update (Business Wire) -8.39%
Nov-02-26 03:05PM	Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London (Business Wire)
Oct-27-26 07:49PM	Arcus Heads Into Third-Quarter Report With Stock Near Lows And Casdatafan Under Scrutiny (Earnings Whispers)
Oct-26-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
10:53PM	Loading…
Oct-21-26 10:53PM	Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock (Business Wire) -19.58%
06:32PM	Arcus Biosciences stock falls on public offering announcement (Investing.com)
04:22PM	Arcus Biosciences Announces Commencement of Public Offering of Common Stock (Business Wire)
10:23AM	Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal (BioPharma Dive)
Oct-20-26 04:34PM	Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal (Investor's Business Daily) +7.27%
09:31AM	Arcus stock tumbles 6% after unveiling casdatifan trial data (Investing.com)
08:30AM	Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer (Business Wire)
Oct-18-26 11:15PM	Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In (Stocktwits)
Oct-09-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Sep-24-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -5.04%
08:30AM	Loading…
Sep-22-26 08:30AM	Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy (Business Wire)
Sep-09-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -8.21%
Aug-26-26 04:05PM	Arcus Biosciences to Participate in Three Upcoming Investor Conferences (Business Wire)
Aug-11-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Aug-05-26 04:05PM	Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update (Business Wire)
Aug-04-26 09:35AM	Earnings To Watch: Arcus Biosciences Inc (RCUS) Q2 2026 -- GF Value Sees 75% Downside (GuruFocus.com)
Jul-27-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jul-24-26 01:01AM	Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Jul-22-26 04:35PM	Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients (Business Wire)
04:30PM	Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer (Business Wire)
Jul-21-26 04:05PM	Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates (Business Wire)
Jul-09-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jul-01-26 11:00AM	New Research Published in Nature Links Clinical Activity with HIF2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan (Business Wire) -6.20%
Jun-24-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) +5.03%
Jun-09-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -6.43%
08:00AM	Loading…
Jun-03-26 08:00AM	Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer (Business Wire)
May-26-26 04:05PM	Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
May-05-26 04:05PM	Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update (Business Wire)
May-04-26 09:19AM	Arcus Biosciences Inc (RCUS) Q1 2026: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-24-26 04:05PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Apr-22-26 05:33AM	Merck adds to pharmas AI push; Roche details MS drug results (BioPharma Dive) +8.56%
Apr-21-26 04:05PM	Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates (Business Wire) +7.83%
Apr-09-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Mar-24-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -5.42% +5.98%
Mar-09-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) +5.97%
Feb-28-26 05:05PM	Arcus Biosciences Q4 Earnings Call Highlights (MarketBeat)
Feb-27-26 12:46PM	RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus (Zacks)
12:08PM	TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line (Zacks)
11:14AM	Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline (Zacks)
Feb-26-26 04:05PM	Arcus Biosciences to Participate in Two Upcoming Investor Conferences (Business Wire)
11:40AM	Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change (Zacks)
10:50AM	Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues (Zacks)
12:05AM	Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Feb-25-26 04:05PM	Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update (Business Wire)
Feb-24-26 07:24AM	Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Report Preview: What to Look For (GuruFocus.com) +7.11%
Feb-23-26 05:00PM	Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer (Business Wire)
Feb-19-26 09:57AM	Here's What Analysts Think About Arcus Biosciences (RCUS) (Insider Monkey)
Feb-11-26 04:05PM	Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates (Business Wire) -6.55%
10:15AM	GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales (Zacks)
Feb-05-26 07:58AM	Rapid Innovation is Reshaping Oncology: Stocks in Focus (Zacks)
Feb-04-26 09:55AM	Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High? (Zacks)
Jan-26-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jan-07-26 04:05PM	Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs (Business Wire) +6.96% -7.97%
Dec-18-25 04:05PM	Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-17-25 07:30AM	This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? (Barchart)
Dec-15-25 09:59AM	RCUS Stock Down on Decision to Discontinue GILD Partnered Study (Zacks)
Dec-12-25 04:10PM	Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak (Investor's Business Daily) -14.36%
08:30AM	Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio (Business Wire)
06:47AM	Arcus cancels work on Gilead-partnered cancer combo after trial setback (BioPharma Dive)
Dec-09-25 06:00PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Nov-18-25 04:05PM	Arcus Biosciences to Participate in Two Upcoming Investor Conferences (Business Wire)
Oct-30-25 11:35PM	Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock (Business Wire)
04:01PM	Arcus Biosciences Announces Commencement of Public Offering of Common Stock (Business Wire)
Oct-28-25 05:55PM	Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +6.88%
04:05PM	Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update (Business Wire)
05:23AM	Arcus Biosciences (RCUS) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
Oct-26-25 06:16AM	Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials (Insider Monkey)
Oct-19-25 07:00PM	Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia (Business Wire)
Oct-12-25 06:05PM	Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study (Business Wire)
Oct-09-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Oct-07-25 04:04PM	How Arcus Biosciences Aims To Take On Merck In Cancer Treatment (Investor's Business Daily) +7.27%
09:40AM	Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
Oct-06-25 08:00AM	Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event (Business Wire) +8.46%
Sep-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Sep-08-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -6.15%
Sep-02-25 04:05PM	Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation (Business Wire) +7.68%
Aug-20-25 04:05PM	Arcus Biosciences to Participate in Three Upcoming Investor Conferences (Business Wire)
Aug-15-25 10:07PM	Jim Cramer on Arcus Biosciences: "Let This Be Your Speculation" (Insider Monkey)
Aug-13-25 08:56PM	Lightning Round: Arcus Biosciences is speculative, it's too risky to fully bank on, says Jim Cramer (CNBC TV)
Aug-06-25 06:10PM	Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 (Zacks)
04:05PM	Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update (Business Wire)
Aug-05-25 05:35PM	Pacira (PCRX) Tops Q2 Earnings Estimates (Zacks)
Jul-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jul-10-25 08:30AM	Arcus Biosciences Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer (Business Wire)
Jul-09-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) +9.76%
Jul-01-25 02:42AM	Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment (Insider Monkey)
Jun-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jun-10-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -9.38%
Jun-01-25 10:45AM	Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response (Business Wire)
May-27-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
May-09-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) +6.28%
May-07-25 10:14AM	Q1 2025 Arcus Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:21AM	Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ... (GuruFocus.com)
May-06-25 06:05PM	Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -9.17%
04:05PM	Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Azoy Alexander	Chief Accounting Officer	Aug 21 '26	Option Exercise	15.44	2,827	43,649	42,408	Aug 24 05:52 PM
Azoy Alexander	Chief Accounting Officer	Aug 21 '26	Sale	30.00	2,827	84,810	39,581	Aug 24 05:52 PM
ALEXANDER AZOY	Officer	Aug 21 '26	Proposed Sale	29.52	2,827	83,453		Aug 21 04:36 PM
Jaen Juan C.	President	Jul 09 '26	Sale	30.05	48,502	1,457,631	842,307	Jul 13 05:36 PM
Jaen Juan C.	President	Jul 10 '26	Sale	28.62	20,067	574,288	822,240	Jul 13 05:36 PM
Juan Jaen	Officer	Jul 09 '26	Proposed Sale	29.96	25,000	749,000		Jul 09 06:31 PM
Juan Jaen	Officer	Jun 24 '26	Proposed Sale	28.80	50,000	1,440,000		Jun 24 06:17 PM
Jaen Juan C.	President	Jun 23 '26	Sale	27.73	15,764	437,100	897,240	Jun 24 05:41 PM
Jaen Juan C.	President	Jun 22 '26	Sale	27.03	9,236	249,661	913,004	Jun 24 05:41 PM
Jaen Juan C.	President	Jun 24 '26	Sale	29.66	6,431	190,740	890,809	Jun 24 05:41 PM
Juan Jaen	Officer	Jun 22 '26	Proposed Sale	27.23	25,000	680,750		Jun 22 06:31 PM
Tang Carolyn C.	General Counsel	Jun 11 '26	Option Exercise	2.57	34,090	87,748	184,607	Jun 12 04:28 PM
Azoy Alexander	Chief Accounting Officer	Jun 01 '26	Sale	25.77	2,562	66,024	39,581	Jun 01 07:23 PM
ALEXANDER AZOY	Officer	Jun 01 '26	Proposed Sale	25.34	2,562	64,921		Jun 01 04:26 PM
Goeltz II Robert C.	Chief Financial Officer	May 11 '26	Sale	25.63	7,763	198,966	84,161	May 12 04:09 PM
Robert C. Goeltz II	Officer	May 11 '26	Proposed Sale	25.63	7,763	198,966		May 11 05:33 PM
JENNIFER JARRETT	Officer	May 06 '26	Proposed Sale	24.60	77,793	1,914,032		May 06 04:11 PM
JENNIFER JARRETT	Officer	Apr 23 '26	Proposed Sale	25.20	53,826	1,356,562		Apr 23 04:46 PM
JENNIFER JARRETT	Officer	Apr 08 '26	Proposed Sale	22.57	70,000	1,579,592		Apr 08 04:21 PM
Jaen Juan C.	President	Jan 05 '26	Sale	21.41	31,823	681,342	922,240	Jan 07 04:15 PM
Juan Jaen	Officer	Jan 05 '26	Proposed Sale	21.77	31,823	692,787		Jan 05 04:58 PM
Goeltz II Robert C.	Chief Financial Officer	Dec 31 '25	Sale	23.38	6,552	153,186	67,924	Jan 02 04:19 PM
Robert C. Goeltz II	Officer	Dec 31 '25	Proposed Sale	23.38	6,552	153,186		Dec 31 06:26 PM
Tang Carolyn C.	General Counsel	Dec 16 '25	Sale	21.88	7,658	167,590	131,544	Dec 18 05:35 PM
Tang Carolyn C.	General Counsel	Dec 17 '25	Sale	22.16	6,810	150,906	124,734	Dec 18 05:35 PM
Markus Richard	Chief Medical Officer	Dec 16 '25	Sale	21.88	5,052	110,559	70,141	Dec 18 05:35 PM
Markus Richard	Chief Medical Officer	Dec 17 '25	Sale	22.16	4,494	99,585	65,647	Dec 18 05:35 PM
Azoy Alexander	Chief Accounting Officer	Dec 18 '25	Sale	22.25	4,343	96,614	18,531	Dec 18 05:35 PM
Azoy Alexander	Chief Accounting Officer	Dec 16 '25	Sale	21.88	2,376	51,997	24,987	Dec 18 05:35 PM
Azoy Alexander	Chief Accounting Officer	Dec 17 '25	Sale	22.16	2,113	46,823	22,874	Dec 18 05:35 PM
Goeltz II Robert C.	Chief Financial Officer	Dec 16 '25	Sale	21.88	6,702	146,669	80,436	Dec 18 05:35 PM
Goeltz II Robert C.	Chief Financial Officer	Dec 17 '25	Sale	22.16	5,960	132,071	74,476	Dec 18 05:35 PM
Jarrett Jennifer	Chief Operating Officer	Dec 16 '25	Sale	21.88	11,225	245,651	203,007	Dec 18 05:35 PM
Jarrett Jennifer	Chief Operating Officer	Dec 17 '25	Sale	22.16	9,983	221,218	193,024	Dec 18 05:35 PM
Jaen Juan C.	President	Dec 16 '25	Sale	21.88	11,225	245,651	355,995	Dec 18 05:35 PM
Jaen Juan C.	President	Dec 17 '25	Sale	22.16	9,983	221,218	346,012	Dec 18 05:35 PM
ROSEN TERRY J	Chief Executive Officer	Dec 16 '25	Sale	21.88	28,947	633,485	2,220,553	Dec 18 05:35 PM
ROSEN TERRY J	Chief Executive Officer	Dec 17 '25	Sale	22.16	25,744	570,474	2,194,809	Dec 18 05:35 PM
ALEXANDER AZOY	Officer	Dec 18 '25	Proposed Sale	22.28	4,343	96,762		Dec 18 04:23 PM
Richard Markus	Officer	Dec 16 '25	Proposed Sale	21.90	10,000	219,000		Dec 15 06:23 PM
Carolyn Tang	Officer	Dec 16 '25	Proposed Sale	21.90	15,000	328,500		Dec 15 06:22 PM
Alexander Azoy	Officer	Dec 16 '25	Proposed Sale	21.90	5,000	109,500		Dec 15 06:22 PM
Robert C. Goeltz, II	Officer	Dec 16 '25	Proposed Sale	21.90	14,000	306,600		Dec 15 06:21 PM
Jennifer Jarrett	Officer	Dec 16 '25	Proposed Sale	21.90	22,000	481,800		Dec 15 06:21 PM
Juan Jaen	Officer	Dec 16 '25	Proposed Sale	21.90	22,000	481,800		Dec 15 06:20 PM
Terry Rosen, Ph.D.	Officer	Dec 16 '25	Proposed Sale	21.90	55,000	1,204,500		Dec 15 06:19 PM
Jaen Juan C.	President	Dec 04 '25	Sale	24.71	82,997	2,050,599	954,063	Dec 05 04:15 PM
Juan Jaen	Officer	Dec 04 '25	Proposed Sale	25.26	82,997	2,096,504		Dec 04 05:10 PM
Azoy Alexander	Chief Accounting Officer	Nov 26 '25	Option Exercise	13.33	1,900	25,327	29,263	Dec 01 06:09 PM
Azoy Alexander	Chief Accounting Officer	Nov 26 '25	Sale	26.00	1,900	49,400	27,363	Dec 01 06:09 PM
ALEXANDER AZOY	Officer	Nov 26 '25	Proposed Sale	24.28	1,900	46,132		Nov 26 04:20 PM
Goeltz II Robert C.	Chief Financial Officer	Nov 26 '25	Sale	25.00	5,000	125,000	87,138	Nov 26 04:07 PM
Robert C. Goeltz II	Officer	Nov 26 '25	Proposed Sale	25.00	5,000	125,000		Nov 26 03:12 PM
Jaen Juan C.	President	Nov 17 '25	Sale	20.31	44,950	913,027	1,042,110	Nov 19 04:39 PM
Jaen Juan C.	President	Nov 18 '25	Sale	19.75	5,050	99,738	1,037,060	Nov 19 04:39 PM
Juan Jaen	Officer	Nov 17 '25	Proposed Sale	19.99	50,000	999,500		Nov 17 06:27 PM

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Co-FounderDr. Terry J. Rosen Ph.D.

Co- Founder & PresidentDr. Juan Carlos Jaen Ph.D.

Principal Financial Officer & CFOMr. Robert C. Goeltz II

Ph.D.Dr. Richard A. Markus M.D.

Co-Founder & Member of Scientific Advisory BoardDr. K. Christopher Garcia Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

RCUS

Arcus Biosciences Inc

Upgrade your Finviz experience

All the Features.
Half the Price.